争议中的重组胶原蛋白事件终于迎来了结局。 6月23日晚间,巨子生物再次发布相关声明,内容回溯了重组胶原蛋白技术的探索历程、现有行业标准、产品生产规范与要求、事件响应和自查,以及下一步措施。 (图源:巨子生物官方微信) 按其所言,2001年,西安巨子生物申请了国内第一项相关发明专利《一种类人胶原蛋白及其生产方法》,基于学术研究将该创新性物质命名为“类人胶原蛋白”,并申请“类人”商标。 这是重组...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.